Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

MLA

Vanita R. Aroda, et al. “Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?” Clinical Diabetes, vol. 36, Apr. 2018, pp. 138–47. EBSCOhost, https://doi.org/10.2337/cd17-0065.

APA

Vanita R. Aroda, Anthony J. Cannon, & Joseph R. Arulandu. (2018). Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One? Clinical Diabetes, 36, 138–147. https://doi.org/10.2337/cd17-0065

Chicago

Vanita R. Aroda, Anthony J. Cannon, and Joseph R. Arulandu. 2018. “Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?” Clinical Diabetes 36 (April): 138–47. doi:10.2337/cd17-0065.